What is Fairtility?
Fairtility is a healthtech innovator dedicated to optimizing IVF success rates through its proprietary AI platform, CHLOE (Cultivating Human Life through Optimal Embryos). The company provides clinicians with a transparent decision support tool that offers granular visibility into laboratory and clinical parameters. Its flagship solution, CHLOE EQ, serves as an advanced embryo grading platform, enabling practitioners to make more informed, data-driven decisions. By digitizing and analyzing the complex variables inherent in embryo development, Fairtility is effectively bridging the gap between laboratory science and clinical application, ultimately aiming to reduce the time to pregnancy for patients worldwide.
How much funding has Fairtility raised?
Fairtility has raised a total of $18.5M across 2 funding rounds:
Angel/Seed
$3.5M
Series A
$15M
Angel/Seed (2020): $3.5M, investors not publicly disclosed
Series A (2022): $15M led by Nacre Capital and Gurnet Point Capital
Key Investors in Fairtility
Nacre Capital
Nacre Capital specializes in creating and growing disruptive start-ups that leverage deep technologies to significantly impact lives, providing hands-on support to scale ventures globally.
Gurnet Point Capital
Gurnet Point Capital is a healthcare-focused investment firm that provides long-term capital to entrepreneurs, operating with a hybrid strategy of venture and private equity in life sciences.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Fairtility?
With the recent infusion of capital, Fairtility is well-positioned to scale its operations and expand the application of the CHLOE platform across the entire IVF continuum. The strategic roadmap includes moving beyond embryo grading to encompass comprehensive infertility cause assessment and transfer optimization. As the company continues to refine its algorithms, it is expected to play a pivotal role in standardizing IVF protocols and improving patient outcomes on a global scale. The focus remains on deepening the integration of AI into clinical workflows, ensuring that reproductive specialists have the necessary tools to navigate the complexities of fertility treatment with unprecedented precision and clarity.
See full Fairtility company page
